Prot #BGB-3111-212: An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared with Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date2/8/19 → 2/8/22

Funding

  • PRA Health Sciences (Prot #BGB-3111-212 // Prot #BGB-3111-212)
  • BeiGene Ltd. (Prot #BGB-3111-212 // Prot #BGB-3111-212)